Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

2.2K

Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes

Emma Magavern1,2, Teck K Khong3

  • 1William Harvey Research Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK.

Drug and Therapeutics Bulletin
|October 27, 2020
PubMed

Insights

Dapagliflozin significantly reduced cardiovascular events in patients with type 2 diabetes. This sodium-glucose cotransporter-2 inhibitor offers cardiovascular protection beyond glucose lowering.

Area of Science:

  • Cardiovascular medicine
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes is associated with a high risk of cardiovascular disease.
  • Existing glucose-lowering therapies do not adequately address cardiovascular risk.
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a novel class of antidiabetic agents.

Purpose of the Study:

  • To evaluate the effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes.
  • To assess the safety and efficacy of dapagliflozin in a broad population with established cardiovascular disease or multiple risk factors.

Main Methods:

  • The study was a randomized, double-blind, placebo-controlled trial involving patients with type 2 diabetes.
  • Participants received dapagliflozin or placebo in addition to standard care.
  • The primary composite endpoint was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Main Results:

  • Dapagliflozin significantly reduced the risk of the primary composite endpoint compared to placebo.
  • The benefit was consistent across subgroups, including patients with and without established cardiovascular disease.
  • No significant increase in adverse events was observed with dapagliflozin.

Conclusions:

  • Dapagliflozin demonstrated significant cardiovascular benefits in patients with type 2 diabetes.
  • The findings support the use of dapagliflozin for reducing cardiovascular risk in this population.
  • SGLT2 inhibition provides cardiorenal protection independent of glycemic control.

Keywords:
cardiovascular diseasesdiabetes mellitus

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.3K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.1K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
418
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
490
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
455
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
429
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
654